GOLDEN evaluates whether a proactive, individualised “first-time-right” guideline-based pharmacological strategy initiated during hospitalisation for ACS or coronary revascularisation improves long-term adherence, risk factor control, and reduces recurrent major adverse cardiovascular events compared with usual stepwise care.